Спастичность: современные терапевтические решения через призму патогенеза
Аннотация
Изучение патофизиологических механизмов спастичности продолжается, однако уже вполне ясна ее гетерогенность, комбинация и взаимовлияние различных механизмов в ее развитии. Оптимальное ведение пациентов зависит от понимания лежащей в основе спастичности физиологии, понимания ее естественного течения, оценки воздействия на пациента и комплексного подхода к минимизации этого воздействия.
Ключевые слова
Об авторах
Р. А. Беляев
Некоммерческое акционерное общество «Карагандинский медицинский университет»
Казахстан
Казахстан
Кафедра неврологии, психиатрии и реабилитации
Караганда
А. В. Мирошниченко
Школа медицины Некоммерческого акционерного общества «Карагандинский медицинский университет»
Казахстан
Казахстан
Анна Викторовна Мирошниченко – интерн , тел.: +7 747 493 8798
Караганда
Список литературы
1. Agarwal S., Patel T., Shah N., Patel B.M. Comparative study of therapeutic response to baclofen vs tolperisone in spasticity [Text] / Agarwal S. Patel T., Shah N., Patel B.M. // Biomed Pharmacother. — 2017. — V. 87. — P.628-635.
2. Bavikatte G., Subramanian G., Ashford S., et al. Early Identification, Intervention and Management of Post-stroke Spasticity: Expert Consensus Recommendations [Text] / Bavikatte G., Subramanian G., Ashford S., Allison R., Hicklin D // J Cent Nerv Syst Dis. — 2021. — V. 13. — P. 117. doi: 10.1177/11795735211036576.
3. Bhidayasiri R., Sringean J., Reich S.G., et al. Red flags phenotyping: A systematic review on clinical features in atypical parkinsonian disorders [Text] / Bhidayasiri R., Sringean J., Reich S.G., et al. // Parkinsonism Relat Disord. — 2019. — V. 59. — P.82-92.
4. Brucculeri M.J., Garcia J. Potassium wasting nephropathy in the setting of tizanidine overdose: a case report [Text] / Brucculeri M.J., Garcia J. // J Med Case Rep. — 2021. — V. 15(1). — P.250.
5. Burridge J.H., Wood D.E., Hermens H.J. et al. Theoretical and methodological considerations in the measurement of spasticity [Text] / Burridge J.H., Wood D.E., Hermens H.J., Voerman G.E., Johnson G.R., van Wijck F., Platz T., Gregoric M., Hitchcock R., Pandyan A.D. // Disabil Rehabil. . — 2005. — V. 27(1-2). — P.69-80.
6. Danilov A.B. The use of tizanidine (Sirdalud) in the treatment of pain and spasm [Text] / Danilov A.B. // RMZh= «RMJ» (Russian Medical Journal). . — 2012. — V. 31. — P.1543.
7. Dressler D., Bhidayasiri R., Bohlega S., et al. Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy [Text] / Dressler D., Bhidayasiri R., Bohlega S., Chana P., Chien H.F., Chung T.M., Colosimo C., Ebke M., Fedoroff K., Frank B., Kaji R., Kanovsky P., Koçer S., Micheli F., Orlova O., Paus S., Pirtosek Z., Relja M., Rosales R.L., Sagástegui-Rodríguez J.A., Schoenle P.W., Shahidi G.A., Timerbaeva S., Walter U., Saberi F.A. // J Neurol. — 2018. — V. 265(4). — P.856-862.
8. Elbasiouny S.M., Moroz D., Bakr M.M., et al. Management of spasticity after spinal cord injury: current techniques and future directions [Text] / Elbasiouny S.M., Moroz D., Bakr M.M., Mushahwar V.K. // Neurorehabil Neural Repair. . — 2010. — V. 24(1). — P.23-33.
9. Ganguly J., Kulshreshtha D., Almotiri M., et al. Muscle Tone Physiology and Abnormalities [Text] / Ganguly J., Kulshreshtha D., Almotiri M., Jog M. // Toxins (Basel). — 2021. — V. 13(4). — P.282.
10. Garbutt J.C., Kampov-Polevoy A.B., Pedersen C., et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial [Text] / Garbutt J.C., Kampov-Polevoy A.B., Pedersen C., Stansbury M., Jordan R., Willing L., Gallop R.J. // Neuropsychopharmacology. — 2021. — V. 46(13). — P.2250-2256.
11. Goyal V., Laisram N., Wadhwa R.K., et al. Prospective Randomized Study of Oral Diazepam and Baclofen on Spasticity in Cerebral Palsy [Text] / Goyal V., Laisram N., Wadhwa R.K., Kothari S.Y. // J Clin Diagn Res. — 2016. — V. 10(6). — RC01-5. doi: 10.7860/JCDR/2016/17067.7975.
12. Gunnarsson S., Lemming D., Alehagen S., et al. Dosing Patterns In Treatment of Disabling Spasticity With Intrathecal Baclofen [Text] / Gunnarsson S., Lemming D., Alehagen S., Berntsson S., Ertzgaard P., Samuelsson K. // Rehabil Nurs. — 2021. — V. 46(6): — P.315-322.
13. Hiersemenzel L.P., Curt A., Dietz V. From spinal shock to spasticity: Neuronal adaptations to a spinal cord injury [Text] / Hiersemenzel L.P., Curt A., Dietz V. // Neurology. — 2000. — V. 54 (8). — P.1574-1582.
14. Hollung S.J., Hägglund G., Gaston M.S., et al. Point prevalence and motor function of children and adolescents with cerebral palsy in Scandinavia and Scotland: a CP-North study [Text] / Hollung S.J., Hägglund G., Gaston M.S., Seid A.K., Lydersen S., Alriksson-Schmidt A.I., Andersen G.L. // Dev Med Child Neurol. — 2021. — V. 63(6). — P.721-728.
15. Holtz K.A., Lipson R., Noonan V.K., et al. Prevalence and Effect of Problematic Spasticity After Traumatic Spinal Cord Injury [Text] / Holtz K.A., Lipson R., Noonan V.K., Kwon B.K., Mills P.B. // Arch Phys Med Rehabil. . — 2017. — V. 98(6). — P.1132-1138.
16. Iskra D.A., Kovalenko A.P., Koshkarev M.A., et al. Spasticity: from pathophysiology to treatment [Text] / Iskra D.A., Kovalenko A.P., Koshkarev M.A., Dyskin D.E. // Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. — 2018. — V. 118(10). — P.108-114. (In Russ.)
17. Jagdale S., Brahmane S., Chabukswar A. Optimization of Microemulgel for Tizanidine Hydrochloride [Text] / Jagdale S., Brahmane S., Chabukswar A. // Antiinflamm Antiallergy Agents Med Chem. . — 2020. —V. 19(2). — P.158-179.
18. Kamen L., Henney H.R. 3rd, Runyan J.D. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury [Text] / Kamen L., Henney H.R. 3rd, Runyan J.D. // Curr Med Res Opin. — 2008. — V. 24(2). — P.425-439.
19. Kent C.N., Park C., Lindsley C.W. Classics in Chemical Neuroscience: Baclofen [Text] / Kent CN, Park C, Lindsley CW // ACS Chem Neurosci. — 2020. — V. 11(12). — P.1740-1755.
20. Khanal R., Oli S., Chan Gomez J., et al. Severe Case of Oral Baclofen Withdrawal Resulting in Mechanical Ventilation [Text] / Khanal R., Oli S., Chan Gomez J., Tahir S., Bhandari B., Komanduri S. // J Investig Med High Impact Case Rep. — 2022. — V. 10. — P.23247096211060584.
21. Kocogullari C.U., Emmiler M., Cemek M., et al. Can dantrolene protect spinal cord against ischemia/reperfusion injury? An experimental study [Text] / Kocogullari C.U., Emmiler M., Cemek M., Sahin O., Aslan A., Ayva E., Tur L., Buyukokuroglu M.E., Demirkan I., Cekirdekci A. // Thorac Cardiovasc Surg. — 2008. — V. 56(7). — P.406-411.
22. Kovalenko A.P., Misikov V.K., Iskra D.A., et al. Tardieu scale in the diagnosis of spasticity [Text] / Kovalenko A.P., Misikov V.K., Iskra D.A. Koshkarev M.A., Sinelnikov K.A. // Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova= S.S. Korsakov Journal of Neurology and Psychiatry. — 2019. — V. 119(9). — P.83-90. (In Russ.)
23. Krause T., Gerbershagen M.U., Fiege M., et al. Dantrolene--a review of its pharmacology, therapeutic use and new developments [Text] / Krause T., Gerbershagen M.U., Fiege M., Weisshorn R., Wappler F. // Anaesthesia — 2004. — V. 59(4). — P.364-373.
24. Lance J.W., Feldman R.G., Young P.R., et al. Spasticity: Disordered Motor Control / Lance J.W., Feldman R.G., Young P.R., Koella W.P. [Text] // Symposium synopsis. — Chicago, IL: USA: Year Book Medical Publishers, 1980. — P.485-494.
25. Leo R.J., Baer D. Delirium associated with baclofen withdrawal: a review of common presentations and management strategies [Text] / Leo R.J., Baer D. // Psychosomatics. — 2005. — V. 46(6). — P.503-507.
26. Li M., Huang Y., Chen R., et al. Efficacy and safety of tolperisone versus baclofen among Chinese patients with spasticity associated with spinal cord injury: a non-randomized retrospective study [Text] / Li M., Huang Y., Chen R., Liu N., Fang S. // Braz J Med Biol Res. — 2021. — V. 54(11). — 293. doi: 10.1590/1414-431X2021e11293.
27. Li X., Jin Y. Irreversible profound symptomatic bradycardia requiring pacemaker after tizanidine/loxoprofen combination therapy: a case report [Text] / Li X., Jin Y. // J Int Med Res. — 2018. — V. 46(6). — P.2466-2469.
28. Lundstrom E., Smits A., Borg J., et al. Fourfold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event [Text] / Erik Lundström., Anja Smits, Jörgen Borg., Andreas Terént // Stroke. — 2010. — V. 41(2). — P.319-324.
29. Luo D., Wu G., Ji Y., et al. The comparative study of clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injury [Text] / Luo D., Wu G., Ji Y., Zhang Z., He F., Mou X., Zhu Q., Yang B. // Saudi Pharm J. — 2020. — V. 25(4). — P.639.
30. Minozzi S., Saulle R., Rösner S. Baclofen for alcohol use disorder [Text] / Minozzi S., Saulle R., Rösner S. // Cochrane Database Syst Rev. — 2018. — V. 11(11). — P.125. doi: 10.1002/14651858.CD012557.pub2.
31. Mukherjee A., Chakravarty A. Spasticity mechanisms - for the clinician. [Text] / Mukherjee A., Chakravarty A. // Front Neurol. — 2010. — V. 1. — P.149. doi: 10.3389/fneur.2010.00149
32. Nakamura-Maruyama E., Miyamoto O., Okabe N., et al. Ryanodine receptors contribute to the induction of ischemic tolerance [Text] / NakamuraMaruyama E., Miyamoto O., Okabe N., Himi N., Feng L., Narita K., Keep R.F., Yamamoto T., Nakamura T. // Brain Res Bull. — 2016. — V. 122. — P.45-53.
33. Peck J., Urits I., Crane J., et al. Oral Muscle Relaxants for the Treatment of Chronic Pain Associated with Cerebral Palsy [Text] / Peck J., Urits I., Crane J., McNally A., Noor N., Patel M., Berger A.A., Cornett E.M., Kassem H., Kaye A.D., Viswanath O. // Psychopharmacol Bull. . — 2020. — V. 50(4 Suppl 1). — P.142-162.
34. Phadke C.P., Balasubramanian C.K., Ismail F., et al. Revisiting physiologic and psychologic triggers that increase spasticity [Text] / Phadke C.P., Balasubramanian C.K., Ismail F., Boulias C. // Am J Phys Med Rehabil. — 2013. — V. 92(4). — P.357-369.
35. Quasthoff S., Möckel C., Zieglgänsberger W., et al. Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects [Text] / Quasthoff S., Möckel C., Zieglgänsberger W., Schreibmayer W. // CNS Neurosci Ther. — 2008. — V. 14(2). — P.107-119.
36. Rabchevsky A.G., Patel S.P., Duale H., et al. Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury [Text] / Rabchevsky A.G., Patel .SP., Duale H., Lyttle T.S., O’Dell C.R., Kitzman P.H. // Spinal Cord. — 2011. — V. 49(1). — P.99-105.
37. Rabchevsky A.G., Patel S.P., Lyttle T.S., et al. Effects of gabapentin on muscle spasticity and both induced as well as spontaneous autonomic dysreflexia after complete spinal cord injury [Text] / Rabchevsky A.G., Patel S.P., Lyttle T.S., Eldahan K.C., O’Dell C.R., Zhang Y., Popovich P.G., Kitzman P.H., Donohue K.D. // Front Physiol. — 2012. — V. 3. — P.329.
38. Ramanathan V., Baskar D., Pari H. ‘Seatbelt Effect’ of Spasticity: Contrasting Velocity Dependence from the Clasp Knife Phenomenon [Text] / Ramanathan V., Baskar D., Pari H. // Ann Indian Acad Neurol. — 2022. — V. 25(3). — P.517-519.
39. Rivelis Y., Zafar N., Morice K. Spasticity. / Rivelis Y., Zafar N., Morice K [Text] // StatPearls. — Treasure Island (FL): StatPearls Publishing, 2022. — PMID: 29939646.
40. Romito J.W., Turner E.R, Rosener JA, et al. Baclofen therapeutics, toxicity, and withdrawal: A narrative review [Text] / Romito J.W., Turner E.R., Rosener J.A., Coldiron L., Udipi A., Nohrn L., Tausiani J., Romito B.T. // SAGE Open Med. — 2021. — V. 9. — P.205. doi: 10.1177/20503121211022197
41. Shanker G., Kumar C.K., Gonugunta C.S., et al. Formulation and evaluation of bioadhesive buccal drug delivery of tizanidine hydrochloride tablets [Text] / Shanker G., Kumar C.K., Gonugunta C.S., Kumar B.V., Veerareddy P.R. // AAPS PharmSciTech. — 2009. — V. 10(2). — P.530-539.
42. Spiller H.A., Bosse G.M., Adamson L.A. Retrospective review of Tizanidine (Zanaflex) overdose [Text] / Spiller H.A., Bosse G.M., Adamson L.A. // Toxicol Clin Toxicol. — 2004. — V. 42(5). — P.593-596.
43. Stamenova P., Koytchev R., Kuhn K., et al. A randomized, double blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke [Text] / Stamenova P., Koytchev R., Kuhn K., Hanasen C., Horvath F., Ramm S., Pongratz D. // Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova= S.S. Korsakov Journal of Neurology and Psychiatry. — 2006. — V. 106(1). — P.34-42.
44. Stetkarova I., Brabec K., Vasko P., et al. Intrathecal Baclofen in Spinal Spasticity: Frequency and Severity of Withdrawal Syndrome [Text] / Stetkarova I., Brabec K., Vasko P., Mencl L. // Pain Physician. — 2015. — V. 18(4). — E633-41. PMID: 26218954
45. Sturgill E.L., Wittwer R.L. Novel Treatment Using Intravenous Dantrolene Sodium for Postoperative Exacerbated Spasticity in Multiple Sclerosis: A Case Report [Text] / Sturgill E.L., Wittwer R.L. // A A Pract. — 2018. — V. 11(1). — P. 25-27.
46. Suponeva N.A., Yusupova D.G., Il’ina K.A., et al. Validation of the Modified Ashworth Scale (Modified Ashworth Scale) in Russia [Text] / Suponeva N.A., Yusupova D.G., Il’ina K.A., Mel’chenko D.A., Butkovskaya A.A., Zhirova E.S., Taratukhina A.S., Zimin A.A., Zaitsev A.B., Klochkov A.S., Lyukmanov R.Kh., Kotovsmolenskii A.M., Khizhnikova A.E., Gatina G.A., Kutlubaev M.A., Piradov M.A. // Annaly klinicheskoi i eksperimental’noinevrologii = Annals of Clinical and Experimental Neurology. — 2020. — V. 14(1). — P.89-96. (InRuss.)
47. Synnot A., Chau M., Pitt V., et al. Interventions for managing skeletal muscle spasticity following traumatic brain injury [Text] / Synnot A., Chau M., Pitt V., O’Connor D., Gruen R.L., Wasiak J., Clavisi O., Pattuwage L., Phillips K. // Cochrane Database Syst Rev. — 2017. — V. 11(11). — CD008929. doi: 10.1002/14651858.
48. Szentesi P., Collet C., Sárközi S., et al. Effects of dantrolene on steps of excitationcontraction coupling in mammalian skeletal muscle fibers [Text] / Szentesi P., Collet C., Sárközi S., Szegedi C., Jona I., Jacquemond V., Kovács L., Csernoch L. // Gen Physiol. — 2001. — V. 118(4). — P.355-375.
49. Tekes K. Basic aspects of the pharmacodynamics of tolperisone, a widely applicable centrally acting muscle relaxant [Text] / Tekes K. // Open Med Chem J. — 2001. — V. 8. — P.17-22.
50. Tilton A. Management of spasticity in children with cerebral palsy [Text] / Tilton A. // Semin Pediatr Neurol. — 2009. — V. 16(2). — P.82-89.
51. Trompetto C., Marinelli L., Mori L., et al. Pathophysiology of spasticity: implications for neurorehabilitation [Text] / Trompetto C., Marinelli L., Mori L., Pelosin E., Currà A., Molfetta L., Abbruzzese G. // Biomed Res Int. — 2014. — V. 3. — P.549-556.
52. Wang J., Shi Y., Yu S., et al. Intranasal administration of dantrolene increased brain concentration and duration [Text] / Wang J., Shi Y., Yu S., Wang Y., Meng Q., Liang G., Eckenhoff M.F., Wei H. // PLoS One. — 2020. — V. 15(3) — doi: 10.1371/journal.pone.0229156
53. Wang Z.M., Law J.H., King N.K., et al. Treatment of severe, disabling spasticity with continuous intrathecal baclofen therapy following acquired brain injury: the experience of a tertiary institution in Singapore [Text] / Wang Z.M., Law J.H., King N.K., Rajeswaran D.K., Soh S., Rao J.P., Ng W.H., Chua K.S. // Singapore Med J. — 2016. — V. 57(1). — P.8-12.
54. Wissel J., Manack A., Brainin M. Toward an epidemiology of poststroke spasticity [Text] / Wissel J, Manack A, Brainin M. // Neurology. — 2013. — V. 80(3 Suppl 2). — P.13-9.
55. Zorowitz R.D., Gillard P.J., Brainin M. Poststroke spasticity: sequelae and burden on stroke survivors and caregivers [Text] / Zorowitz R.D., Gillard P.J., Brainin M. // Neurology. — 2013. — V. 80(3 Suppl 2). — P.45-52.
Рецензия
Для цитирования:
Беляев Р.А., Мирошниченко А.В. Спастичность: современные терапевтические решения через призму патогенеза. Медицина и экология. 2022;(3):5-11.
For citation:
Belyaev R.A., Miroshnichenko A.V. Spasticity: modern therapeutic solutions through the prism of pathogenesis. Medicine and ecology. 2022;(3):5-11.
Просмотров: 114
Послать статью по эл. почте 